Work for Heat Biologics, Inc.?

Claim Your Profile

Heat Biologics, Inc. Logo Image

Heat Biologics, Inc.

Heat Biologics, Inc. Banner Image

Most Recent Annual Report

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

2019 Annual Report and Form 10K

Heat Biologics, Inc.

Heat Biologics, Inc. has reached its limit for free report views.

Upgrade your company profile to unlock all of your annual report content on AnnualReports.com

Archived Annual Reports

About Heat Biologics, Inc.

11-50 Employees
Based in Durham, North Carolina

Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial.

Ticker:
HTBX
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol